Close Menu

NEW YORK — ProterixBio said on Wednesday that it has licensed a SARS-CoV-2 serology test from Massachusetts General Hospital.

According to ProterixBio, the ELISA-based test measures antibodies that bind to the receptor binding domain of the SARS-CoV-2 spike protein. The test can be run using dried blood samples from finger pricks and includes a means of calibration so measurements can be tracked over time.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.